Drug details
Beleodaq (belinostat for injection for intravenous use)
type of Antineoplastics HDAc Inhibitors
Beleodaq (belinostat) for Injection is a histone deacetylase inhibitor used to treat patients with relapsed or refractory peripheral T-cell lymphoma (PTCL).
This drug may have the following side effects:
- dizziness,
- headache
- cough
- nausea
- diarrhea
- fever
- itching
- vomiting
- low blood pressure,
- chills
- low blood potassium (hypokalemia),
- infusion site pain
- fatigue
- anemia
- constipation
- shortness of breath
- rash
- swelling of extremities
- loss of appetite
- abdominal pain
- low blood platelets (thrombocytopenia),
- phlebitis,
- prolonged QT,
- pneumonia, and
- infection.
The following drugs are related to Beleodaq, either as a replacement or used together:
- Aliqopa (copanlisib for injection, for intravenous use)
- Breyanzi (lisocabtagene maraleucel suspension for intravenous infusion)
- Vyxeos (daunorubicin and cytarabine for injection)
- Decadron (dexamethasone)
- Idhifa (enasidenib tablets)
- Zevalin (ibritumomab tiuxetan)
- Zynlonta (loncastuximab tesirine-lpyl for injection)
- Rituxan (rituximab)
- Truxima (rituximab-abbs injection)
- Ukoniq (umbralisib tablets)